<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02089997</url>
  </required_header>
  <id_info>
    <org_study_id>178-001</org_study_id>
    <secondary_id>JapicCTI-142463</secondary_id>
    <secondary_id>JapicCTI-R171017</secondary_id>
    <nct_id>NCT02089997</nct_id>
  </id_info>
  <brief_title>Special Drug Use Surveillance on Long-term Use of Sodium Risedronate Tablets (Benet 75 mg Tablets) (12-month Treatment Survey)</brief_title>
  <official_title>Benet 75 mg Tablets Special Drug Use Surveillance: Long-term Use (12-month Treatment Survey)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and efficacy of sodium risedronate
      tablets (Benet 75 mg Tablets) in osteoporosis patients in daily medical practice, as well as
      to examine &quot;the status of treatment compliance&quot; - i.e., whether sodium risedronate tablets
      are taken properly in accordance with the prescribed once-monthly regimen
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This surveillance was designed to evaluate the safety and efficacy of sodium risedronate
      tablets (Benet 75 mg Tablets) as well as to evaluate the status of treatment compliance in
      osteoporosis patients in daily medical practice.

      The usual dosage for adult is 75 mg of sodium risedronate administered orally with a
      sufficient volume (approximately 180 mL) of water once monthly after waking. For at least 30
      minutes after administration, patients should avoid lying in a supine position and should
      avoid taking food, drink (except for water) or other oral drugs. For more details, see the
      &quot;Precautions related to dosage and administration&quot; section of the package insert.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 27, 2013</start_date>
  <completion_date type="Actual">April 30, 2016</completion_date>
  <primary_completion_date type="Actual">April 30, 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Who Experience at Least One Adverse Drug Reactions (ADRs)</measure>
    <time_frame>Up to Month 12</time_frame>
    <description>Adverse drug reactions are defined as adverse events (AEs) which are in the investigator's opinion of causal relationship to the study treatment. AEs are defined as any unfavorable and unintended signs, symptoms or diseases temporally associated with administration of sodium risedronate, whether or not it was considered related to the treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Mean Lumbar Spine (L2-L4) Bone Mineral Density (BMD) at Final Assessment</measure>
    <time_frame>Baseline and final assessment (up to Month 12)</time_frame>
    <description>BMD was measured with Dual-energy X-ray Absorptiometry. Reporting data are the change in BMD in the second to the fourth lumbar vertebrae, L2 to L4, and the averages of L2 to L4 at end of study relative to baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Femur (Neck Region) BMD at Final Assessment</measure>
    <time_frame>Baseline and final assessment (up to Month 12)</time_frame>
    <description>BMD was measured with Dual-energy X-ray Absorptiometry. Reporting data are the change in BMD in the femur (neck region) at end of study relative to baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Femur (Total Proximal Femur) BMD at Final Assessment</measure>
    <time_frame>Baseline and final assessment (up to Month 12)</time_frame>
    <description>BMD was measured with Dual-energy X-ray Absorptiometry. Reporting data are the change in BMD in the total proximal femur (whole bone, trochanteric region, and neck region) at end of study relative to baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Radius BMD at Final Assessment</measure>
    <time_frame>Baseline and final assessment (up to Month 12)</time_frame>
    <description>BMD was measured with Dual-energy X-ray Absorptiometry. Reporting data are the change in BMD in the radius at end of study relative to baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Bone Metabolism Markers Serum Type 1 Collagen Cross-linked N-telopeptide (NTX) at Final Assessment</measure>
    <time_frame>Baseline and final assessment (up to Month 12)</time_frame>
    <description>Blood samples for serum bone turnover markers were collected at specified visits according to the study schedule.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Bone Metabolism Markers Serum Tartrate-resistant Acid Phosphatase 5b (TRACP-5b) at Final Assessment</measure>
    <time_frame>Baseline and final assessment (up to Month 12)</time_frame>
    <description>Blood samples for serum bone turnover markers were collected at specified visits according to the study schedule.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Bone Metabolism Markers Serum Bone-type Alkaline Phosphatase (BAP) at Final Assessment</measure>
    <time_frame>Baseline and final assessment (up to Month 12)</time_frame>
    <description>Blood samples for serum bone turnover markers were collected at specified visits according to the study schedule.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Bone Metabolism Markers Serum Procollagen 1 N-terminal Peptide (P1NP) at Final Assessment</measure>
    <time_frame>Baseline and final assessment (up to Month 12)</time_frame>
    <description>Blood samples for serum bone turnover markers were collected at specified visits according to the study schedule.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Bone Metabolism Markers Urinary Type 1 Collagen Cross-linked N-telopeptide (NTX) at Final Assessment</measure>
    <time_frame>Baseline and final assessment (up to Month 12)</time_frame>
    <description>Urine samples for urinary bone turnover markers were collected at specified visits according to the study schedule.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Height</measure>
    <time_frame>Baseline and final assessment (up to Month 12)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Had Lumbar Backache at Final Assessment</measure>
    <time_frame>Final assessment (Month 12)</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">3304</enrollment>
  <condition>Osteoporosis</condition>
  <arm_group>
    <arm_group_label>75 mg of sodium risedronate</arm_group_label>
    <description>75 mg of sodium risedronate is administered orally with a sufficient volume (approximately 180 mL) of water once monthly after waking.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sodium Risedronate</intervention_name>
    <description>Sodium risedronate tablets</description>
    <arm_group_label>75 mg of sodium risedronate</arm_group_label>
    <other_name>Benet 75mg Tablets</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Osteoporosis
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Osteoporosis patients

        Exclusion Criteria:

          -  None
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Takeda</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <study_first_submitted>March 14, 2014</study_first_submitted>
  <study_first_submitted_qc>March 14, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 18, 2014</study_first_posted>
  <results_first_submitted>July 27, 2017</results_first_submitted>
  <results_first_submitted_qc>February 2, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">October 19, 2018</results_first_posted>
  <last_update_submitted>February 2, 2018</last_update_submitted>
  <last_update_submitted_qc>February 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pharmacological therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Risedronic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants took part in the study at 606 investigative sites in Japan from 27-May 2013 to 30-April 2016 .</recruitment_details>
      <pre_assignment_details>Participants with a historical diagnosis of osteoporosis were enrolled to receive sodium risedronate 75 milligram (mg) for up to 12 months as per routine medical practice.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Sodium Risedronate 75 mg</title>
          <description>Sodium risedronate 75 mg, tablet, orally, once monthly for up to 12 months.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3304"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3058"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="246"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Case report forms uncollected</title>
              <participants_list>
                <participants group_id="P1" count="99"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="147"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety Analysis Set was defined as all participants who were enrolled and completed the study.</population>
      <group_list>
        <group group_id="B1">
          <title>Sodium Risedronate 75 mg</title>
          <description>Sodium risedronate 75 mg, tablet, orally, once monthly for up to 12 months.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3058"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt; 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="373"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2678"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2817"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="241"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <description>All participants were enrolled in Japan.</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Japan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3058"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Pregnancy Status</title>
          <description>This baseline characteristic was analyzed only in female participants.</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Pregnant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not pregnant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2329"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="488"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt; 50.0 kg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1050"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 50.0 kg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="953"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1055"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <description>Body Mass Index = weight (kg)/[height (m)^2]</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt; 18.5kg/m^2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="162"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 18.5kg/m^2 &lt; 25.0kg/m^2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1108"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 25.0kg/m^2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="291"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1497"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Osteoporosis Class</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Primary Osteoporosis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2696"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Secondary Osteoporosis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="232"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="130"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Predisposition to Hypersensitivity</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Had No Predisposition to Hypersensitivity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2658"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Had Predisposition to Hypersensitivity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="151"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="249"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Medical Complications</title>
          <description>Complications defined as a disease or a health condition for each participant at the start of study. Complications were classified as congenital anomalies, endocrine disorders, hematologic disorders, psychiatric and nervous system disorders, cardiovascular disorders, respiratory disorders, gastrointestinal (GI) disorders, renal disease and other complications. Other complications included all complications except for those mentioned above. Participants may be represented in more than 1 category.</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Had Presence of Medical Complications</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2649"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Had No Presence of Medical Complications</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="409"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Medical History（not Inclusive of a History of Fractures）</title>
          <description>Medical history defined as a disease or a health condition for each participant before start of the study. Medical history was classified as congenital anomalies, hematologic disorders, psychiatric and nervous system disorders, cardiovascular disorders, respiratory disorders, GI disorders, hepatic and biliary disorders, renal disease and other medical history and Bone Fractures were out of scope for Medical history in this study. Other medical history included all medical history except for those mentioned above. Participants may be represented in more than 1 category.</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Had Medical History</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="587"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Had No Medical History</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2264"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="207"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Pretreatment Osteoporosis Drug</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Had Treatment Drug</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1149"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Had No Treatment Drug</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1909"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Concomitant Medication</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Had Concomitant Medication</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2512"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Had No Concomitant Medication</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="546"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Experience at Least One Adverse Drug Reactions (ADRs)</title>
        <description>Adverse drug reactions are defined as adverse events (AEs) which are in the investigator's opinion of causal relationship to the study treatment. AEs are defined as any unfavorable and unintended signs, symptoms or diseases temporally associated with administration of sodium risedronate, whether or not it was considered related to the treatment.</description>
        <time_frame>Up to Month 12</time_frame>
        <population>Safety Analysis Set was defined as all participants who were enrolled and completed the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Sodium Risedronate 75 mg</title>
            <description>Sodium risedronate 75 mg, tablet, orally, once monthly for up to 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Experience at Least One Adverse Drug Reactions (ADRs)</title>
          <description>Adverse drug reactions are defined as adverse events (AEs) which are in the investigator's opinion of causal relationship to the study treatment. AEs are defined as any unfavorable and unintended signs, symptoms or diseases temporally associated with administration of sodium risedronate, whether or not it was considered related to the treatment.</description>
          <population>Safety Analysis Set was defined as all participants who were enrolled and completed the study.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3058"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="231"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Mean Lumbar Spine (L2-L4) Bone Mineral Density (BMD) at Final Assessment</title>
        <description>BMD was measured with Dual-energy X-ray Absorptiometry. Reporting data are the change in BMD in the second to the fourth lumbar vertebrae, L2 to L4, and the averages of L2 to L4 at end of study relative to baseline.</description>
        <time_frame>Baseline and final assessment (up to Month 12)</time_frame>
        <population>The efficacy assessment population was defined as participants who completed the study and had efficacy data at baseline and post-baseline time points available. Here number of participants analyzed are participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Sodium Risedronate 75 mg</title>
            <description>Sodium risedronate 75 mg, tablet, orally, once monthly for up to 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Mean Lumbar Spine (L2-L4) Bone Mineral Density (BMD) at Final Assessment</title>
          <description>BMD was measured with Dual-energy X-ray Absorptiometry. Reporting data are the change in BMD in the second to the fourth lumbar vertebrae, L2 to L4, and the averages of L2 to L4 at end of study relative to baseline.</description>
          <population>The efficacy assessment population was defined as participants who completed the study and had efficacy data at baseline and post-baseline time points available. Here number of participants analyzed are participants evaluable for this outcome measure.</population>
          <units>Percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="545"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.700" spread="12.118"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Femur (Neck Region) BMD at Final Assessment</title>
        <description>BMD was measured with Dual-energy X-ray Absorptiometry. Reporting data are the change in BMD in the femur (neck region) at end of study relative to baseline.</description>
        <time_frame>Baseline and final assessment (up to Month 12)</time_frame>
        <population>The efficacy assessment population was defined as participants who completed the study and had efficacy data at baseline and post-baseline time points available. Here number of participants analyzed are participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Sodium Risedronate 75 mg</title>
            <description>Sodium risedronate 75 mg, tablet, orally, once monthly for up to 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Femur (Neck Region) BMD at Final Assessment</title>
          <description>BMD was measured with Dual-energy X-ray Absorptiometry. Reporting data are the change in BMD in the femur (neck region) at end of study relative to baseline.</description>
          <population>The efficacy assessment population was defined as participants who completed the study and had efficacy data at baseline and post-baseline time points available. Here number of participants analyzed are participants evaluable for this outcome measure.</population>
          <units>Percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="393"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.008" spread="5.473"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Femur (Total Proximal Femur) BMD at Final Assessment</title>
        <description>BMD was measured with Dual-energy X-ray Absorptiometry. Reporting data are the change in BMD in the total proximal femur (whole bone, trochanteric region, and neck region) at end of study relative to baseline.</description>
        <time_frame>Baseline and final assessment (up to Month 12)</time_frame>
        <population>The efficacy assessment population was defined as participants who completed the study and had efficacy data at baseline and post-baseline time points available. Here number of participants analyzed are participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Sodium Risedronate 75 mg</title>
            <description>Sodium risedronate 75 mg, tablet, orally, once monthly for up to 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Femur (Total Proximal Femur) BMD at Final Assessment</title>
          <description>BMD was measured with Dual-energy X-ray Absorptiometry. Reporting data are the change in BMD in the total proximal femur (whole bone, trochanteric region, and neck region) at end of study relative to baseline.</description>
          <population>The efficacy assessment population was defined as participants who completed the study and had efficacy data at baseline and post-baseline time points available. Here number of participants analyzed are participants evaluable for this outcome measure.</population>
          <units>Percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="424"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.745" spread="5.180"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Radius BMD at Final Assessment</title>
        <description>BMD was measured with Dual-energy X-ray Absorptiometry. Reporting data are the change in BMD in the radius at end of study relative to baseline.</description>
        <time_frame>Baseline and final assessment (up to Month 12)</time_frame>
        <population>The efficacy assessment population was defined as participants who completed the study and had efficacy data at baseline and post-baseline time points available. Here number of participants analyzed are participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Sodium Risedronate 75 mg</title>
            <description>Sodium risedronate 75 mg, tablet, orally, once monthly for up to 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Radius BMD at Final Assessment</title>
          <description>BMD was measured with Dual-energy X-ray Absorptiometry. Reporting data are the change in BMD in the radius at end of study relative to baseline.</description>
          <population>The efficacy assessment population was defined as participants who completed the study and had efficacy data at baseline and post-baseline time points available. Here number of participants analyzed are participants evaluable for this outcome measure.</population>
          <units>Percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="569"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.173" spread="6.909"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Bone Metabolism Markers Serum Type 1 Collagen Cross-linked N-telopeptide (NTX) at Final Assessment</title>
        <description>Blood samples for serum bone turnover markers were collected at specified visits according to the study schedule.</description>
        <time_frame>Baseline and final assessment (up to Month 12)</time_frame>
        <population>The efficacy assessment population was defined as participants who completed the study and had efficacy data at baseline and post-baseline time points available. Here number of participants analyzed are participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Sodium Risedronate 75 mg</title>
            <description>Sodium risedronate 75 mg, tablet, orally, once monthly for up to 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Bone Metabolism Markers Serum Type 1 Collagen Cross-linked N-telopeptide (NTX) at Final Assessment</title>
          <description>Blood samples for serum bone turnover markers were collected at specified visits according to the study schedule.</description>
          <population>The efficacy assessment population was defined as participants who completed the study and had efficacy data at baseline and post-baseline time points available. Here number of participants analyzed are participants evaluable for this outcome measure.</population>
          <units>Percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="174"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.024" spread="27.863"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Bone Metabolism Markers Serum Tartrate-resistant Acid Phosphatase 5b (TRACP-5b) at Final Assessment</title>
        <description>Blood samples for serum bone turnover markers were collected at specified visits according to the study schedule.</description>
        <time_frame>Baseline and final assessment (up to Month 12)</time_frame>
        <population>The efficacy assessment population was defined as participants who completed the study and had efficacy data at baseline and post-baseline time points available. Here number of participants analyzed are participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Sodium Risedronate 75 mg</title>
            <description>Sodium risedronate 75 mg, tablet, orally, once monthly for up to 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Bone Metabolism Markers Serum Tartrate-resistant Acid Phosphatase 5b (TRACP-5b) at Final Assessment</title>
          <description>Blood samples for serum bone turnover markers were collected at specified visits according to the study schedule.</description>
          <population>The efficacy assessment population was defined as participants who completed the study and had efficacy data at baseline and post-baseline time points available. Here number of participants analyzed are participants evaluable for this outcome measure.</population>
          <units>Percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="449"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-32.016" spread="30.219"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Bone Metabolism Markers Serum Bone-type Alkaline Phosphatase (BAP) at Final Assessment</title>
        <description>Blood samples for serum bone turnover markers were collected at specified visits according to the study schedule.</description>
        <time_frame>Baseline and final assessment (up to Month 12)</time_frame>
        <population>The efficacy assessment population was defined as participants who completed the study and had efficacy data at baseline and post-baseline time points available. Here number of participants analyzed are participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Sodium Risedronate 75 mg</title>
            <description>Sodium risedronate 75 mg, tablet, orally, once monthly for up to 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Bone Metabolism Markers Serum Bone-type Alkaline Phosphatase (BAP) at Final Assessment</title>
          <description>Blood samples for serum bone turnover markers were collected at specified visits according to the study schedule.</description>
          <population>The efficacy assessment population was defined as participants who completed the study and had efficacy data at baseline and post-baseline time points available. Here number of participants analyzed are participants evaluable for this outcome measure.</population>
          <units>Percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="128"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-19.449" spread="28.058"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Bone Metabolism Markers Serum Procollagen 1 N-terminal Peptide (P1NP) at Final Assessment</title>
        <description>Blood samples for serum bone turnover markers were collected at specified visits according to the study schedule.</description>
        <time_frame>Baseline and final assessment (up to Month 12)</time_frame>
        <population>The efficacy assessment population was defined as participants who completed the study and had efficacy data at baseline and post-baseline time points available. Here number of participants analyzed are participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Sodium Risedronate 75 mg</title>
            <description>Sodium risedronate 75 mg, tablet, orally, once monthly for up to 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Bone Metabolism Markers Serum Procollagen 1 N-terminal Peptide (P1NP) at Final Assessment</title>
          <description>Blood samples for serum bone turnover markers were collected at specified visits according to the study schedule.</description>
          <population>The efficacy assessment population was defined as participants who completed the study and had efficacy data at baseline and post-baseline time points available. Here number of participants analyzed are participants evaluable for this outcome measure.</population>
          <units>Percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="217"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-46.302" spread="30.482"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Bone Metabolism Markers Urinary Type 1 Collagen Cross-linked N-telopeptide (NTX) at Final Assessment</title>
        <description>Urine samples for urinary bone turnover markers were collected at specified visits according to the study schedule.</description>
        <time_frame>Baseline and final assessment (up to Month 12)</time_frame>
        <population>The efficacy assessment population was defined as participants who completed the study and had efficacy data at baseline and post-baseline time points available. Here number of participants analyzed are participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Sodium Risedronate 75 mg</title>
            <description>Sodium risedronate 75 mg, tablet, orally, once monthly for up to 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Bone Metabolism Markers Urinary Type 1 Collagen Cross-linked N-telopeptide (NTX) at Final Assessment</title>
          <description>Urine samples for urinary bone turnover markers were collected at specified visits according to the study schedule.</description>
          <population>The efficacy assessment population was defined as participants who completed the study and had efficacy data at baseline and post-baseline time points available. Here number of participants analyzed are participants evaluable for this outcome measure.</population>
          <units>Percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="194"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-22.010" spread="60.634"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Height</title>
        <time_frame>Baseline and final assessment (up to Month 12)</time_frame>
        <population>The efficacy assessment population was defined as participants who completed the study and had efficacy data at baseline and post-baseline time points available. Here number of participants analyzed are participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Sodium Risedronate 75 mg</title>
            <description>Sodium risedronate 75 mg, tablet, orally, once monthly for up to 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Height</title>
          <population>The efficacy assessment population was defined as participants who completed the study and had efficacy data at baseline and post-baseline time points available. Here number of participants analyzed are participants evaluable for this outcome measure.</population>
          <units>Centimeter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="806"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.37" spread="1.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Had Lumbar Backache at Final Assessment</title>
        <time_frame>Final assessment (Month 12)</time_frame>
        <population>The efficacy assessment population was defined as participants who completed the study and had efficacy data at baseline and post-baseline time points available. Here number of participants analyzed are participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Sodium Risedronate 75 mg</title>
            <description>Sodium risedronate 75 mg, tablet, orally, once monthly for up to 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Had Lumbar Backache at Final Assessment</title>
          <population>The efficacy assessment population was defined as participants who completed the study and had efficacy data at baseline and post-baseline time points available. Here number of participants analyzed are participants evaluable for this outcome measure.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2052"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="663"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Baseline up to Month 12</time_frame>
      <desc>At each visit the investigator had to document any occurrence of AEs and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment. Only ADRs were collected in this study. Participants may be represented in more than 1 category.</desc>
      <group_list>
        <group group_id="E1">
          <title>Sodium Risedronate 75 mg</title>
          <description>Sodium risedronate 75 mg, tablet, orally, once monthly for up to 12 months.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 14.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="3058"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac hypertrophy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3058"/>
              </event>
              <event>
                <sub_title>Aortic valve stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3058"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <description>The reasons of events are not determined because assessment findings were insufficient to specify the reason.</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3058"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3058"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3058"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3058"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3058"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3058"/>
              </event>
              <event>
                <sub_title>Collagen disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3058"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3058"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3058"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3058"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0.5</frequency_threshold>
        <default_vocab>MedDRA 14.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="71" subjects_at_risk="3058"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="3058"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="3058"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="3058"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Director</name_or_title>
      <organization>Takeda</organization>
      <phone>+1-877-825-3327</phone>
      <email>trialdisclosures@takeda.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

